Fludarabine: profile and news

CV Therapeutics' Ranexa May Have Trouble Meeting Street Targets  Mar 2, 2006
The company said operating expenses rose 25% from the year-ago period, attributing the increase to the launch of a new indication for heart drug Aceon. ... - Forbes

CV Therapeutics Reports 2005 Fourth Quarter and Full Year ...  Mar 1, 2006
...deployment of the Company's national cardiovascular specialty sales force and other product support and awareness programs to co- promote ACEON(R) (perindopril ... - MSN Money

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  Feb 28, 2006
...hiring, primarily in connection with its commercialization efforts to promote Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril ... - PR Newswire (press release),

CV Therapeutics fourth-quarter loss widens  Mar 1, 2006
Operating expenses rose 25 percent to $75.5 million, from last year's $60.5 million, due to higher costs from the company's co-promotion of Aceon, its drug for ... - BusinessWeek

CV Therapeutics Announces Four Abstracts Accepted for Presentation ...  Mar 3, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PharmaLive.com (press release),

UPDATE 1-CV Therapeutics 4th-quarter loss widens  Mar 1, 2006
...pharmacies by the end of March. Marketing costs for its hypertension drug Aceon also weighed on results. CV Therapeutics stock, which had ... - Reuters

CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as ...  09 Feb 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON(R) (perindopril erbumine) Tablets. ... - PR Newswire (press release),

FDA Approves Ranexa  Jan 27, 2006
CV Therapeutics' approved products include Ranexa(TM) (ranolazine extended-release tablets) and ACEON® (perindopril erbumine) Tablets. ... - Yahoo! News (press release)

CV Therapeutics Appoints Joseph M. Davie, MD, Ph.D. to Board of ...  Jan 13, 2006
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON(R) (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and ... - PR Newswire (press release),

CV Therapeutics Gets FDA OK To Sell Ranexa In Angina  Jan 30, 2006
CV Therapeutics' sales representatives already have been getting to know cardiovascular doctors through sales of the ACE inhibitor Aceon (perindopril erbumine ... - BioWorld Online (subscription),

Caldwell: An update on Veterans' benefits  Dec 7, 2005
...a co-pay of 22$. On the list were the ACE inhibitors Aceon, Accupriul and Altace and Univasc. The calcium channel blockers Covera ... - Norwell Mariner,

CV Therapeutics May See Strong Ranexa Potential  Nov 17, 2005
...there could be upside from other applications of Ranexa beyond second-line refractory angina and from [CV's hypertension treatment] Aceon," Piper analyst ... - Forbes

Data From Evaluation of Ranolazine in Chronic Angina (ERICA) Study ...  Nov 16, 2005
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON(R) (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and ... - PR Newswire (press release),

New Ascot-BPLA Substudy Shows Coversyl's Cardioprotective Benefits ...  Nov 14, 2005
R), PREXUM(R), COVERENE(R), COVERSUM(R), PROCAPTAN(R), ARMIX(R), and marketed by Solvay Pharmaceutical and CV Therapeutics under the trade name of ACEON(R) in ... - news aktuell (Pressemitteilung),

Coversyl's Cardioprotective Benefits Go Beyond Blood Pressure ...  Nov 25, 2005
PREXUM®, COVERENE®, COVERSUM®, PROCAPTAN®, ARMIX®, and marketed by Solvay Pharmaceutical and CV Therapeutics under the trade name of ACEON® in the USA. ... - Medical News Today (press release),

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace ...  Sep 15, 2005
...to 54 non-executive employees due to additional hiring, primarily in connection with its commercialization efforts to co-promote ACEON® (perindopril erbumine ... - Yahoo! News (press release)

Regadenoson Phase 3 Data Presented as Late-Breaker at American ...  Oct 2, 2005
CV Therapeutics currently has three programs in commercial or late-stage development: ACEON® (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and ... - Yahoo! News (press release)

Obama against review of stress disorder cases  Oct 2, 2005
ACE (angiotensin converting enzyme) inhibitors for treatment of hypertension. Brand names: Altace, Aceon, Accupril and Univasc. ... - Daily Press,

Analysis: Blood-pressure guideline blurred  Sep 16, 2005
ASCOT researchers said that patients receiving the angiotensin-converting enzyme, or ACE inhibitor perindopril (ACEON) and the calcium channel blocker ... - Monsters and Critics.com,

Two New Treatment Advances For Coronary Artery Disease Patients  Sep 11, 2005
PREXANIL®, PREXUM®, COVERENE®, COVERSUM®, PROCAPTAN® and marketed by Solvay Pharmaceutical and CV Therapeutics under the trade name of ACEON® in the US. ... - Medical News Today (press release),

New Hope For Elderly Heart Attack Survivors  Sep 11, 2005
PREXANIL®, PREXUM®, COVERENE®, COVERSUM®, PROCAPTAN® and marketed by Solvay Pharmaceutical and CV Therapeutics under the trade name of ACEON® in the US. - I-Newswire.com (press release)

Amlodipine-Based Regimen Better Than Atenolol for Hypertension  Sep 9, 2005
Of those, 9,639 patients were randomized to a daily regimen of 5 to 10 mg of amlodipine, with perindopril (Aceon) as required, while 9,618 patients were given ... - Medscape (subscription)

The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.